For many years, the treatment of type 2 diabetes focused almost exclusively on controlling blood sugar levels. Lowering glucose was the main goal, and while important, this approach often overlooked the broader health risks faced by people with diabetes—particularly heart disease and kidney problems. Today, however, a newer class of medications known as SGLT inhibitors is reshaping this perspective. Among them, sotagliflozin has emerged as a unique option that goes beyond glucose control, offering benefits for both the heart and kidneys.
In this blog, we’ll explore what sotagliflozin is, how it works, its cardiovascular benefits, and its expanding role in patient care.
What is Sotagliflozin?
Sotagliflozin (brand name Inpefa in the U.S.) is part of a class of medications called SGLT inhibitors. Unlike other drugs in its class, sotagliflozin has a dual mechanism of action:
- It blocks SGLT2 proteins in the kidney, reducing glucose reabsorption and lowering blood sugar.
- It also inhibits SGLT1 proteins in the intestines, which decreases glucose absorption after meals.
This dual activity makes sotagliflozin a distinctive therapy with broader potential effects compared to traditional SGLT2 inhibitors like empagliflozin or dapagliflozin.
The Link Between Diabetes and Heart Disease
People with diabetes are at a significantly higher risk of developing cardiovascular disease. In fact, heart disease is the leading cause of death among individuals with diabetes. Historically, many glucose-lowering therapies showed little to no impact on cardiovascular outcomes, and in some cases even increased risks.
This gap pushed researchers to look for treatments that could both control glucose and protect the heart. Sotagliflozin is one of the drugs now stepping into this role.
Cardiovascular Benefits of Sotagliflozin
Several clinical trials have highlighted sotagliflozin’s benefits for patients with heart conditions:
- Reduced Risk of Heart Failure Hospitalizations: Studies show that sotagliflozin lowers the risk of hospitalization for heart failure in patients with diabetes, chronic kidney disease, or existing heart disease. This is especially important because heart failure is one of the most common and costly complications linked to diabetes.
- Lower Rates of Cardiovascular Death: By improving heart function and reducing strain on the cardiovascular system, sotagliflozin has been associated with fewer fatal cardiovascular events.
- Renal Protection: Beyond the heart, sotagliflozin also helps protect kidney function, reducing the progression of chronic kidney disease. This kidney-protective effect is crucial, as diabetes is the leading cause of end-stage renal disease worldwide.
Expanding Indications: Who Can Benefit?
Originally developed for type 2 diabetes, sotagliflozin’s approval has now expanded to include patients with heart failure—even those without diabetes. This shift reflects a growing recognition that the drug’s benefits extend beyond blood sugar control.
Some of the groups who may benefit include:
- Patients with heart failure with reduced or preserved ejection fraction (HFrEF and HFpEF).
- Individuals at high risk of cardiovascular events, even without diabetes.
- Patients with chronic kidney disease, where sotagliflozin can slow disease progression.
By addressing multiple conditions at once, sotagliflozin exemplifies a new era of multi-benefit medications.
How Does It Compare to Other SGLT2 Inhibitors?
Sotagliflozin shares many benefits with other SGLT2 inhibitors like dapagliflozin (Farxiga) and empagliflozin (Jardiance), but its additional SGLT1 inhibition sets it apart. This may provide stronger post-meal glucose control and potentially broader cardiovascular protection.
However, like all medications, sotagliflozin has potential side effects, including urinary tract infections, dehydration, and gastrointestinal symptoms due to its intestinal effects. Careful patient selection and monitoring are essential.
The Future of Sotagliflozin
The approval of sotagliflozin for heart failure and its ongoing studies in kidney disease signal a shift in how we view diabetes medications. No longer limited to blood sugar management, drugs like sotagliflozin are becoming cornerstones of cardiovascular and renal care.
As more evidence emerges, we may see even wider use of sotagliflozin across different patient populations, potentially changing standard treatment guidelines worldwide.
Key Takeaways
- Sotagliflozin is a dual SGLT1 and SGLT2 inhibitor that reduces blood sugar while offering heart and kidney protection.
- Clinical trials show significant reductions in heart failure hospitalizations and cardiovascular deaths.
- It is now approved not just for diabetes but also for heart failure, including in patients without diabetes.
- Its unique dual mechanism provides additional benefits compared to other SGLT2 inhibitors.
- Sotagliflozin represents a growing movement toward holistic medications that treat more than one condition.
Download DoseMed to stay on track and maximize the long-term benefits.
Related reading: a wider guide to medications used for diabetes, and metformin in combination with atorvastatin and lisinopril.